The who, when, why, and how of PET Amyloid imaging in management of Alzheimer’s disease-review of literature and interesting images
Amyloid imaging using positron emission tomography (PET) has an emerging role in the management of Alzheimer’s disease (AD). The basis of this imaging is grounded on the fact that the hallmark of AD is the histological detection of beta amyloid plaques (Aβ) at post mortem autopsy. Currently, there a...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI
2019
|
| Online Access: | http://psasir.upm.edu.my/id/eprint/82617/ http://psasir.upm.edu.my/id/eprint/82617/1/The%20who.pdf |
| _version_ | 1848859315952156672 |
|---|---|
| author | Suppiah, Subapriya Didier, Mellanie Anne Vinjamuri, Sobhan |
| author_facet | Suppiah, Subapriya Didier, Mellanie Anne Vinjamuri, Sobhan |
| author_sort | Suppiah, Subapriya |
| building | UPM Institutional Repository |
| collection | Online Access |
| description | Amyloid imaging using positron emission tomography (PET) has an emerging role in the management of Alzheimer’s disease (AD). The basis of this imaging is grounded on the fact that the hallmark of AD is the histological detection of beta amyloid plaques (Aβ) at post mortem autopsy. Currently, there are three FDA approved amyloid radiotracers used in clinical practice. This review aims to take the readers through the array of various indications for performing amyloid PET imaging in the management of AD, particularly using 18F-labelled radiopharmaceuticals. We elaborate on PET amyloid scan interpretation techniques, their limitations and potential improved specificity provided by interpretation done in tandem with genetic data such as apolipiprotein E (APO) 4 carrier status in sporadic cases and molecular information (e.g., cerebral spinal fluid (CSF) amyloid levels). We also describe the quantification methods such as the standard uptake value ratio (SUVr) method that utilizes various cutoff points for improved accuracy of diagnosing AD, such as a threshold of 1.122 (area under the curve 0.894), which has a sensitivity of 92.3% and specificity of 90.5%, whereas the cutoff points may be higher in APOE ε4 carriers (1.489) compared to non-carriers (1.313). Additionally, recommendations for future developments in this field are also provided. |
| first_indexed | 2025-11-15T12:27:24Z |
| format | Article |
| id | upm-82617 |
| institution | Universiti Putra Malaysia |
| institution_category | Local University |
| language | English |
| last_indexed | 2025-11-15T12:27:24Z |
| publishDate | 2019 |
| publisher | MDPI |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | upm-826172020-10-17T21:41:19Z http://psasir.upm.edu.my/id/eprint/82617/ The who, when, why, and how of PET Amyloid imaging in management of Alzheimer’s disease-review of literature and interesting images Suppiah, Subapriya Didier, Mellanie Anne Vinjamuri, Sobhan Amyloid imaging using positron emission tomography (PET) has an emerging role in the management of Alzheimer’s disease (AD). The basis of this imaging is grounded on the fact that the hallmark of AD is the histological detection of beta amyloid plaques (Aβ) at post mortem autopsy. Currently, there are three FDA approved amyloid radiotracers used in clinical practice. This review aims to take the readers through the array of various indications for performing amyloid PET imaging in the management of AD, particularly using 18F-labelled radiopharmaceuticals. We elaborate on PET amyloid scan interpretation techniques, their limitations and potential improved specificity provided by interpretation done in tandem with genetic data such as apolipiprotein E (APO) 4 carrier status in sporadic cases and molecular information (e.g., cerebral spinal fluid (CSF) amyloid levels). We also describe the quantification methods such as the standard uptake value ratio (SUVr) method that utilizes various cutoff points for improved accuracy of diagnosing AD, such as a threshold of 1.122 (area under the curve 0.894), which has a sensitivity of 92.3% and specificity of 90.5%, whereas the cutoff points may be higher in APOE ε4 carriers (1.489) compared to non-carriers (1.313). Additionally, recommendations for future developments in this field are also provided. MDPI 2019-06 Article PeerReviewed text en http://psasir.upm.edu.my/id/eprint/82617/1/The%20who.pdf Suppiah, Subapriya and Didier, Mellanie Anne and Vinjamuri, Sobhan (2019) The who, when, why, and how of PET Amyloid imaging in management of Alzheimer’s disease-review of literature and interesting images. Diagnostics, 9 (2). ISSN 2075-4418 10.3390/diagnostics9020065 |
| spellingShingle | Suppiah, Subapriya Didier, Mellanie Anne Vinjamuri, Sobhan The who, when, why, and how of PET Amyloid imaging in management of Alzheimer’s disease-review of literature and interesting images |
| title | The who, when, why, and how of PET Amyloid imaging in management of Alzheimer’s disease-review of literature and interesting images |
| title_full | The who, when, why, and how of PET Amyloid imaging in management of Alzheimer’s disease-review of literature and interesting images |
| title_fullStr | The who, when, why, and how of PET Amyloid imaging in management of Alzheimer’s disease-review of literature and interesting images |
| title_full_unstemmed | The who, when, why, and how of PET Amyloid imaging in management of Alzheimer’s disease-review of literature and interesting images |
| title_short | The who, when, why, and how of PET Amyloid imaging in management of Alzheimer’s disease-review of literature and interesting images |
| title_sort | who, when, why, and how of pet amyloid imaging in management of alzheimer’s disease-review of literature and interesting images |
| url | http://psasir.upm.edu.my/id/eprint/82617/ http://psasir.upm.edu.my/id/eprint/82617/ http://psasir.upm.edu.my/id/eprint/82617/1/The%20who.pdf |